AMBER VANDIVER: Open Payments
NPI 1528697174 · OSAGE BEACH, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$565 in 27 payments from 8 companies in 2025. Trend: 2023 $14 · 2024 $298 · 2025 $565
Food & beverage: $565
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 6 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $120 |
| Novo Nordisk Inc | 4 | $88 |
| ABBVIE INC. | 3 | $53 |
| AstraZeneca Pharmaceuticals LP | 2 | $53 |
| Neurocrine BioSciences, Inc. | 2 | $48 |
| Lilly USA, LLC | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
Products named: Dexcom G6 Transmitter, CAPLYTA, Wegovy, BREZTRI, INGREZZA, ABILIFY MAINTENA, VRAYLAR, UBRELVY.
Industry payments across MO — which companies pay providers there.
